Tadalafil contraindications: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Tadalafil}} {{CMG}}; {{AE}} {{PB}} '''''For patient information, click <u>here'''''</u> ==Contraindications== <ref ...") |
|||
Line 8: | Line 8: | ||
==Contraindications== | ==Contraindications== | ||
===Concomitant Organic Nitrates=== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADCIRCA (TADALAFIL) TABLET [UNITED THERAPEUTICS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae | publisher = | date = | accessdate = 7 February 2014 }}</ref> | Do not use ADCIRCA in patients who are using any form of organic nitrate, either regularly or intermittently. ADCIRCA potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and ADCIRCA on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)]. | ||
===Hypersensitivity Reactions=== | |||
ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADCIRCA (TADALAFIL) TABLET [UNITED THERAPEUTICS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae | publisher = | date = | accessdate = 7 February 2014 }}</ref> | |||
==References== | ==References== |
Revision as of 22:41, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here
Contraindications
Concomitant Organic Nitrates
Do not use ADCIRCA in patients who are using any form of organic nitrate, either regularly or intermittently. ADCIRCA potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and ADCIRCA on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.2)].
Hypersensitivity Reactions
ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis.[1]
References
- ↑ "ADCIRCA (TADALAFIL) TABLET [UNITED THERAPEUTICS CORPORATION]". Retrieved 7 February 2014.